热门资讯> 正文
AbbVie认为第三季度，IPR&D和里程碑费用的全年影响是负面的
2025-10-04 04:55
- AbbVie (NYSE:ABBV) said it will incur a negative impact of $1.50 to GAAP and non-GAAP diluted earnings per share in Q3 due to acquired IPR&D and milestones expense of $2.7B.
- As a result, the company now sees Q3 adjusted diluted earnings per share of $1.74-$1.78. Consensus is $3.27.
- AbbVie also said that its full-year EPS guidance range is now $10.38-$10.58. Consensus is $11.97.
More on AbbVie
- AbbVie: Wins Accumulating While We Wait For Next BD Steps
- AbbVie For Healthy Dividend Growth
- AbbVie: Best Time To Sell In 5 Years (Rating Downgrade)
- AbbVie and Calico win FDA fast track tag for kidney drug
- INCY and ABBV lead S&P 500 healthcare gainers in Q3; MOH and ALGN lag
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
